Damora Therapeutics, Inc. filings document public-company governance, executive compensation, auditor matters, leadership changes, and capital-structure disclosures for its biotechnology business. Recent 8-K reports cover changes in certifying accountant and principal financial officer responsibilities, while proxy materials describe compensation and governance matters.
The company’s regulatory record also reflects its Delaware corporate status, Nasdaq-listed common stock, equity-award arrangements, and disclosure controls around material events following its transition to a mutCALR-focused biotechnology pipeline.
Damora Therapeutics, Inc. General Counsel Winslow Garrett reported routine equity compensation activity involving restricted stock units (RSUs) and a small share sale tied to taxes. On July 3, 2026, 680 RSUs were settled into 680 shares of common stock at a stated price of $0.00 per share as part of their scheduled vesting from a January 3, 2024 award. On the same date, 640 RSUs from this award remained outstanding. On July 6, 2026, 245 shares of common stock were sold at $29.98 per share to cover tax obligations in connection with the RSU vesting under the company’s 2020 Equity Incentive Plan, which the filing describes as a mandated, non-discretionary sale. Following these transactions, Garrett holds 2,289 shares of Damora Therapeutics common stock directly.
DMRA provides a Form 144 notice listing proposed sales of Common Stock. The filing names Maxim Group as broker and lists planned cash sales tied to option exercises dated 01/03/2025 and 10/09/2024. The reported lot sizes include 5,000, 5,787, and 7,213 shares.
The notice specifies Common Stock and shows a trading market of NASDAQ. The filing supplies broker contact information and the dates 06/22/2026 associated with the filing entries.
Damora Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected Michael Landsittel and Cameron Turtle, D.Phil, as Class III directors to serve until the 2029 annual meeting. An advisory vote approved the compensation of the company’s named executive officers, and stockholders indicated a preference to hold this Say-on-Pay vote every year. Stockholders also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. A quorum was present, with 55,009,938 shares represented out of 60,303,212 shares outstanding on the record date.
Damora Therapeutics ownership update: Amendment No. 1 to a Schedule 13G/A reports that Point72-related entities and Steven A. Cohen beneficially hold 1,193,708 shares of Damora Therapeutics common stock, equal to 2.0% of the class as of the close of business on March 31, 2026. The shares are reported as held by an investment fund managed by Point72 Asset Management, L.P., with voting and dispositive power shared among Point72 entities and Mr. Cohen pursuant to an investment management agreement.
Damora Therapeutics amended a Schedule 13G/A to disclose reporting by Jain Global LLC, Jain Holdings LLC, and Robert Jain concerning Common Stock (CUSIP 36322Q206). The filing states the Reporting Persons hold 0.0% of the class and reports $0.00001 par value per share; ownership rows on the cover show zeros for voting and dispositive powers.
The amendment is signed by an authorized signatory and notes a previously filed power of attorney; it is an ownership disclosure for holders of 5% or less.
Damora Therapeutics disclosed that Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 3,783,000 shares of Common Stock, representing 6.27% of the class. The percentage is calculated using March 17, 2026 outstanding shares of 60,303,212. The statement, filed on a Schedule 13G, identifies Avoro as investment adviser holding the shares on behalf of Avoro Life Sciences Fund LLC and names Dr. Aghazadeh as portfolio manager. The filing lists sole voting and dispositive power over the reported 3,783,000 shares and provides business addresses for the reporting persons.
Damora Therapeutics, Inc. reported a larger net loss as it ramps up development of its mutCALR-targeted pipeline and strengthens its balance sheet. For the quarter ended March 31, 2026, net loss was $27.8 million versus $2.5 million a year earlier, driven mainly by a jump in research and development spending.
Research and development expenses rose to $23.8 million, including $17.0 million related to Paragon under the Paragon Option Agreement and $5.0 million of stock-based compensation from the Paramora warrant obligation. General and administrative costs increased to $7.0 million as the company scales its public-company and infrastructure footprint.
Damora ended the quarter with $532.9 million in cash and cash equivalents, boosted by a February 2026 underwritten offering that raised approximately $295.5 million net, and an accumulated deficit of $515.1 million. Management believes current cash resources can fund operations for at least one year. The company is focusing on its mutCALR portfolio (DMR-001, DMR-002, DMR-003) for myeloproliferative neoplasms and has deprioritized further development of GB3226.
Damora Therapeutics, Inc. executive Brian Burkavage, SVP of Finance, reported a stock option position on a Form 3. The option gives him the right to buy common stock at $32.00 per share for 312,535 underlying shares, expiring on December 15, 2035.
According to the footnote, 25% of this option will vest on December 15, 2026, with the remainder vesting in equal monthly installments through December 15, 2029, subject to his continued service with the company.
Damora Therapeutics, Inc. announced a finance leadership change. The Board determined that, effective May 1, 2026, Lori Firmani will cease serving as Chief Financial Officer, principal financial officer, and principal accounting officer. Her departure benefits will follow the company’s Executive Separation Benefits Plan, with base salary continuation and pro-rated target bonus paid in a single lump sum, a $6,000 health savings account contribution, and full acceleration of all outstanding equity awards, subject to her signing a separation agreement and release.
The Board appointed Brian Burkavage, currently Senior Vice President, Finance, to serve as principal financial officer and principal accounting officer effective at the same time. Burkavage, age 43, has held senior finance roles at IO Biotech, Passage Bio, and Aclaris Therapeutics and previously spent 11 years at Ernst & Young. He will enter into Damora’s standard executive indemnification agreement, and the company states he has no disclosable related-party transactions or family relationships with directors or executives.